American Century Companies Inc. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

American Century Companies Inc. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,793,846 shares of the biopharmaceutical company's stock after buying an additional 33,411 shares during the period. American Century Companies Inc. owned 1.37% of Alnylam Pharmaceuticals worth $584,957,000 as of its most recent SEC filing.

• Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

A number of other hedge funds have also added to or reduced their stakes in ALNY. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in Alnylam Pharmaceuticals by 203.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company's stock worth $76,195,000 after acquiring an additional 189,128 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after acquiring an additional 185,783 shares in the last quarter. SCS Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth $46,194,000. Finally, Orbis Allan Gray Ltd boosted its position in shares of Alnylam Pharmaceuticals by 11.0% during the first quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock valued at $441,462,000 after buying an additional 162,121 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALNY. Barclays upped their price objective on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an "overweight" rating in a research report on Friday, October 31st. Oppenheimer restated an "outperform" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a "buy" rating in a research report on Monday, October 6th. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 11th. Finally, Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $482.17.

• 3 biotech powerhouses poised to thrive amid sector rebound

Check Out Our Latest Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $436.38 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a market capitalization of $57.65 billion, a PE ratio of -176.67 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a 50-day simple moving average of $457.30 and a two-hundred day simple moving average of $390.58.

Insiders Place Their Bets

• Argenx's 28% Surge & Promising Product Propel Investor Confidence

In other news, CEO Yvonne Greenstreet sold 10,000 shares of the company's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the transaction, the chief executive officer owned 65,409 shares in the company, valued at $29,517,119.43. This represents a 13.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the transaction, the executive vice president directly owned 54,052 shares of the company's stock, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 78,328 shares of company stock valued at $35,705,793. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

• Five stocks we like better than Alnylam Pharmaceuticals
• The 3 Best Fintech Stocks to Buy Now
• MP Materials Stock Soared After Earnings—Here’s the Real Reason
• Using the MarketBeat Dividend Yield Calculator
• Why Palantir Slide May Be a Setup for a Long-Term Opportunity
• Diversification Can Smooth Returns And Mitigate Portfolio Risk
• Attention Income Investors: This REIT Is on Sale

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here